[go: up one dir, main page]

KR100902947B1 - Composition Containing Culture of Bacillus subtilis MORI for Growth Promotion - Google Patents

Composition Containing Culture of Bacillus subtilis MORI for Growth Promotion Download PDF

Info

Publication number
KR100902947B1
KR100902947B1 KR1020070056104A KR20070056104A KR100902947B1 KR 100902947 B1 KR100902947 B1 KR 100902947B1 KR 1020070056104 A KR1020070056104 A KR 1020070056104A KR 20070056104 A KR20070056104 A KR 20070056104A KR 100902947 B1 KR100902947 B1 KR 100902947B1
Authority
KR
South Korea
Prior art keywords
weight
growth
culture
bacillus subtilis
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020070056104A
Other languages
Korean (ko)
Other versions
KR20080082417A (en
Inventor
성수일
황교열
이재연
강경돈
박영식
조용석
오경환
김영훈
Original Assignee
주식회사 피앤비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 피앤비 filed Critical 주식회사 피앤비
Publication of KR20080082417A publication Critical patent/KR20080082417A/en
Application granted granted Critical
Publication of KR100902947B1 publication Critical patent/KR100902947B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254Acanthopanax or Eleutherococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286Carthamus (distaff thistle)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/40Cornaceae (Dogwood family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/894Dioscoreaceae (Yam family)
    • A61K36/8945Dioscorea, e.g. yam, Chinese yam or water yam
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/306Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/832Bacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 성장촉진효과가 있는 성장촉진용 조성물로서, 가시오가피와 홍화씨, 산약, 산수유, 복령, 녹각 및 인삼의 추출물(한약추출물)과 바실러스 서브틸리스 모리(Bacillus subtilis MORI) 배양물을 혼합시켜 함유함으로써 유년기 내지 사춘기의 성장을 촉진시킬 수 있는 성장촉진용 조성물에 관한 것이다.The present invention relates to a composition for promoting growth in the growth-promoting effect, and gasiohgapi safflower, Yam, Cornus officinalis, of Poria cocos, overgrown antler and ginseng extract (herbal extract) and Bacillus subtilis memory (Bacillus subtilis MORI) The present invention relates to a growth promoting composition capable of promoting the growth of infancy and adolescence by mixing and containing a culture.

바실러스 서브틸리스 모리, 가시오가피, 한약재, 성장 Bacillus subtilis mori, Prickly Pear, Herbal Medicine, Growth

Description

바실러스 서브틸리스 모리 배양물을 함유하는 성장촉진용 조성물{Composition Containing Culture of Bacillus subtilis MORI for Growth Promotion}Composition for promoting growth containing Bacillus subtilis Mori culture {Composition Containing Culture of Bacillus subtilis MORI for Growth Promotion}

도 1은 랫트(Rat) 쥐를 이용한 성장시험으로 생리식염수 급여(대조구)군, 가시오가피 및 6종의 한약재(GSW) 추출물 급여군, 가시오가피 및 6종의 한약재 추출물과 바실러스 배양물 급여군, 가시오가피 및 6종의 한약재 추출물과 락토바실러스 배양물 급여군, 가시오가피 및 6종의 한약재 추출물과 계면활성제 급여군 및 가시오가피 및 6종의 한약재 추출물과 바실러스 배양물, 락토바실러스 배양물 및 계면활성제(Sorbitan monostearate)의 혼합 급여군에 대하여 2주간 체중 증가율을 나타내는 그래프임.1 is a rat (Rat) rat growth test using physiological saline (control) group, prickly scabies and 6 kinds of Chinese herbal medicine (GSW) extract feed group, prickly scabies and 6 kinds of medicinal herb extracts and Bacillus culture feeding group, prickly scabies and 6 Herbal Medicine Extracts and Lactobacillus Culture Feeding Group, Prickly Ginseng and 6 Herbal Medicine Extracts and Surfactant Feeding Group and 6 Herbal Medicine Extracts and Bacillus Culture, Lactobacillus Culture and Surfactant (Sorbitan monostearate) This is a graph showing weight gain rate for 2 weeks for the mixed pay group.

도 2는 랫트(Rat) 쥐를 이용한 성장시험으로 생리식염수 급여군(대조구), 기존 제품과 가시오가피 및 6종의 한약재 추출물 급여군(기존), 기존 제품과 가시오가피 및 6종의 한약재 추출물에 바실러스 배양물 혼합급여군(개선1), 기존 제품과 가시오가피 및 6종의 한약재 추출물에 비타민 AD3 및 계면활성제 급여군(개선2), 기존 제품과 가시오가피 및 6종의 한약재 추출물에 바실러스 배양물, 비타민 AD3 및 계면활성제를 혼합한 급여군(개선3)에 대하여 2주간 성장률을 나타내는 그래프임.Figure 2 is a growth test using rat rats physiological saline feeding group (control), Bacillus culture in conventional products and thorny opi and 6 kinds of medicinal herb extracts feed group (existing), conventional products and thorny opi and 6 medicinal herb extracts Vitamin AD 3 and Surfactant Feeding Group (improvement 2), Existing Products and Prunus scabbard and 6 Herbal Extracts, Improved Bacillus Culture, Vitamin AD This is a graph showing growth rate for 2 weeks with respect to the feeding group (improvement 3) mixed with 3 and surfactant.

도 3은 랫트(Rat) 쥐를 이용한 성장시험으로 생리식염수 급여군(대조구), 기존 제품과 가시오가피 및 6종의 한약재 추출물 급여군(기존), 기존 제품과 가시오가피 및 6종의 한약재 추출물에 바실러스 배양물 혼합 급여군(개선1), 기존 제품과 가시오가피 및 6종의 한약재 추출물에 비타민 AD3, 계면활성제 급여군(개선2), 기존 제품과 가시오가피 및 6종의 한약재 추출물에 바실러스 배양물, 비타민 AD3, 계면활성제를 혼합 급여군(개선3)에 대한 IGF-1를 측정한 도면임.Figure 3 is a growth test using rat rat physiological saline feeding group (control), Bacillus culture in conventional products and thorny opi and six kinds of medicinal herb extracts feed group (existing), conventional products and thorny opi and six medicinal herb extracts Vitamin AD 3 in water-adjusted group (Improvement 1), extracts of conventional products and thorny opi and 6 kinds of herbal medicine, Bacillus culture, vitamin AD 3 is a diagram measuring IGF-1 for a surfactant-adjusted group (improvement 3).

본 발명은 성장촉진 효과가 있는 성장촉진용 조성물로서, 보다 상세하게는 가시오가피와 홍화씨, 산약, 산수유, 복령, 녹각 및 인삼(이하, ‘홍화씨, 산약, 산수유, 복령, 녹각 및 인삼’을 ‘6종 한약재’라 함.)의 추출물과 바실러스 서브틸리스 모리(Bacillus subtilis MORI) 배양물(이하, ‘바실러스 배양물’라 함)을 함유하여 성장을 촉진시킬 수 있는 성장촉진용 조성물에 관한 것이다.The present invention is a growth promoting composition having a growth promoting effect, and more specifically, thorn ogapi and safflower seeds, acid pills, cornus, bokyeong, green and ginseng (hereinafter referred to as' safflower seed, mountain pills, cornus, bokyeong, green and ginseng '' 6 kind of medicinal plants "referred to.) extracts and Bacillus subtilis Mori (Bacillus of subtilis MORI) relates to a growth promoting composition capable of promoting growth by containing a culture (hereinafter referred to as 'bacillus culture').

통상 '성장'이라 함은 성숙에 수반되는 크기의 변화로서 복잡한 생물학적 현상이나, 일반적으로 사용되는 의미는 신장의 증가를 일컫는 것으로, 신장의 증가는 연골조직합성, 골격길이 성장과 골격의 광범위한 골 성장을 포함하는 골격대사를 통하여 이루어진다(Crotton. PM. et al.(1997), Clin. Chem., 43(9); 1577~81 참조). 'Growth' is a complex biological phenomenon that is a change in size accompanied by maturation, but the term commonly used refers to an increase in kidneys. An increase in kidneys is associated with cartilage tissue synthesis, skeletal length growth, and extensive bone growth in the skeleton. Made through skeletal metabolism, including (Crotton. PM. Et . al . (1997), Clin. Chem., 43 (9); 1577-81).

성장에 기여하는 주 인자는 골격길이의 증가인데 뼈의 종적증가는 연골내골화에 일어나며, 뼈의 성장은 연골조직이 골 조직으로 전환되어 일어난다. 연골내골화는 주로 사지의 장관골에서 일어나며, 뼈의 폭증가는 섬유성막에서 직접적으로 골격조직으로 발달한다. The main factor contributing to the growth is the increase in skeletal length. The increase in bone length is caused by cartilage within the cartilage, and the bone growth is caused by the conversion of cartilage tissue to bone tissue. Cartilage occurs mainly in the long bones of the extremities, and the increase in bone develops directly into the skeletal tissue in the fibrous membrane.

성장도를 평가하는 측정지표는 다양하지만 동물시험에서의 측정지표는 체중(g)을 가장 많이 측정하며, 대퇴부의 길이, 무게, 부피, 밀도, 면적, 무기질 함량, 무기질 밀도측정을 통한 골성장 정도, 골밀도 등을 측정한다. 아이지에프-1(Insulin-like growth factor-1, 이하, 'IGF-1')은 펩타이드 호르몬으로 간세포에서 발현하여 혈중으로 방출되므로 혈중의 아이지에프-1 농도의 측정은 간접적으로 성장호르몬 분비를 평가 할 수 있다.(전 징경 등(2000), 대한소아내분비학회지, 5(1); 75 ~ 82) Although there are various indicators for assessing growth, the measurement indicators in animal studies measure the most weight (g), and bone growth through femoral length, weight, volume, density, area, mineral content, and mineral density. And bone density. Insulin-like growth factor-1 (hereinafter referred to as 'IGF-1') is a peptide hormone expressed in hepatocytes and released into the blood. Therefore, the measurement of the concentration of IGFF in the blood indirectly evaluates growth hormone secretion. (Former Jing Kyung et al. (2000), Korean Journal of Pediatric Endocrinology, 5 (1); 75-82)

IGF-1은 성장호르몬의 영향을 받아 인슐린의 표적조직에서 당질, 지질, 단백질의 합성을 자극하여 인슐린과 비슷한 작용을 한다. 즉 세포의 증식과 분화에 관여함으로서 성장에 영향을 미친다. 조골세포와 연골세포에 IGF-1 수용체가 존재하며, IGF-1은 연골세포의 효과를 통해서 골격성장을 유도하며, 조골세포에 대해 유사분열을 유도하고, 조골세포에 의한 콜라겐(Collagen)합성을 촉진하며, 골격 형성을 촉진한다. IGF-1은 체내에서 일정한 농도를 유지하므로 측정이 비교적 용이하며, 내인성 성장호르몬 분비 평가에 유용한 진단적 지표이다. IGF-1 acts similar to insulin by stimulating the synthesis of sugars, lipids and proteins in the target tissues of insulin under the influence of growth hormone. In other words, it affects growth by being involved in cell proliferation and differentiation. IGF-1 receptors are present in osteoblasts and chondrocytes. IGF-1 induces skeletal growth through the effect of chondrocytes, induces mitosis for osteoblasts, and collagen synthesis by osteoblasts. Promotes skeletal formation. IGF-1 is relatively easy to measure because it maintains a constant concentration in the body and is a useful diagnostic indicator for evaluating endogenous growth hormone secretion.

국민소득증대에 따라 유년기 성장에 큰 관심의 대상이 되고 있으며, 영양섭취수준증가, 생활환경개선, 생활습관의 합리화 등 유년기에서부터 사춘기의 평균신 장, 체중 등이 점차 증가 개선되고 있으며, 큰 신장의 이점으로 인한 인식변화에 따라 성장을 촉진하기 위한 방안 등이 크게 대두되고 있으며, 최근, 가시오가피를 포함한 한약 추출물로 성장촉진 추출 및 이를 함유하는 약학적 제제에 대한 연구가 진행되고 있다.Increasing national income has attracted much attention to childhood growth, and the average height and weight of adolescents are gradually improving and improving in childhood, such as increasing nutritional intake levels, improving the living environment, and rationalizing lifestyles. As a result of the change of perception, a plan for promoting growth has emerged, and recently, researches on growth promotion extraction and pharmaceutical preparations containing the same have been conducted.

상기 가시오가피는 오가과에 속한 낙엽관목인 자오가의 뿌리와 근경 및 수피를 건조한 것으로 카로틴(Carotene), 리구스트린(Ligustrin) 등이 함유되어 있는 것으로 알려져 있으며, 현재까지 알려진 가시오가피의 약리 작용으로 진정작용, 항스트레스 작용, 면역증강작용, 이완작용, 소염작용 등이 보고되어 있다. 가시오가피의 약리작용에 기초하여 다양한 용도가 연구되었는데, 여드름 및 뾰루지를 치료(대한민국 특허공개 제2000-9820호)하였고, 발기부전 치료에도 효과가 있음(대한민국 특허공개 제2000-74868호)을 기술하였으며, 항스트레스 조성물(대한민국 특허등록 제160402호)에 가시오가피를 주요성분으로 사용하였다.The thorny ogapi is known to contain carotene, ligustrin, etc., which are dried roots, roots and roots of bark, which is a deciduous shrub belonging to the oga family, and sedative action by pharmacological action , Antistress action, immune enhancing action, relaxation action, anti-inflammatory action has been reported. Various uses have been studied based on the pharmacological action of prickly pear, and it has been described that it treats acne and rashes. In the anti-stress composition (Korean Patent Registration No. 160402), prickly pear skin was used as a main ingredient.

또한, 상기 가시오가피를 한약 추출물과 함유시킨 성장촉진추출물 및 이를 함유하는 약학적 제제(대한민국 공개특허 제2003-30337호)가 알려져 있으나, 그 효과 정도가 여전히 기대에 못 미치는 문제점이 있었다.In addition, growth promoting extracts containing the thorny scabies extract and pharmaceutical preparations containing the same (Korean Patent Publication No. 2003-30337) are known, but the degree of effect is still less than expected.

이에, 본 발명자들은 더욱 성장촉진 효과가 개선된 제제의 발명을 연구하던 중 가시오가피와 상기 6종 한약재로부터 추출된 한약 추출물에 바실러스 배양물을 더하게 되면 성장 촉진효과가 크게 개선됨을 발견하여 본 발명을 완성하게 되었다.Thus, the present inventors found that the growth promoting effect is greatly improved by adding a Bacillus culture to the medicinal herb extract extracted from the thorny scabies and the six herbal medicines while studying the invention of the formulation with improved growth promoting effect. It was completed.

따라서, 본 발명은 가시오가피와 상기 6종 한약재의 한약 추출물과 바실러스 배양물을 함유하는 성장촉진용 조성물을 제공하는데 있다.Accordingly, the present invention is to provide a growth promoting composition containing the thorny opi and the herbal extracts and Bacillus culture of the six herbs.

본 발명은 가시오가피 10-90 중량 %, 홍화씨 0.1-50 중량%, 산약 0.1-50 중량%, 산수유 0.1-50 중량%, 복령 0.1-50 중량%, 녹각 0.1-50 중량%, 및 인삼 0.1-50 중량%를 포함하는 혼합물로부터 추출된 한약 추출물 100 중량부 및 바실러스 배양물 0.1-10 중량부를 포함하는 것을 특징으로 하는 성장촉진용 조성물에 관한 것이다.The present invention is 10-90% by weight, 0.1-50% by weight safflower seed, 0.1-50% by weight, wild corn oil 0.1-50% by weight, 0.1-50% by weight of Bokryeong, 0.1-50% by weight, green ginseng 0.1-50% It relates to a growth promoting composition comprising 100 parts by weight of the herbal extract extracted from the mixture comprising a weight percent and 0.1-10 parts by weight of Bacillus culture.

또한, 본 발명은 상기 조성물이 건조 또는 액상 형태인 것을 특징으로 하는 성장촉진용 조성물에 관한 것이다.The present invention also relates to a growth promoting composition, characterized in that the composition is in a dry or liquid form.

이하, 본 발명을 보다 상세히 설명하도록 한다.Hereinafter, the present invention will be described in more detail.

먼저, 본 발명에 사용되는 바실러스 서브틸리스 모리(Bacillus subtilis MORI)균은 대두발효에 사용되는 균과 유사한 균으로서 전분질 분해능이 우수하고, 단백질 분해능이 우수할 뿐 아니라 지방질이나 고분자의 탄수화물을 분해하여 저분자의 아미노산, 핵산, 지방산, 비타민, 알카로이드, 점성이 있는 폴리머(Polymer) 등을 생산하는 특징이 있으며, 그 배양물의 액상이나 건조물을 사람이나 동물이 섭취할 경우 매우 성장촉진과 관련하여 유익하며, 전통적으로 안전한 균 또는 배양물이다. First, Bacillus subtilis mori ( Bacillus) used in the present invention subtilis MORI) is a bacterium similar to that used for soybean fermentation. It has excellent starch resolution, excellent protein resolution, and breaks down carbohydrates of fats and polymers, and has low molecular weight amino acids, nucleic acids, fatty acids, vitamins, alkaloids, and viscosities. It has the characteristic of producing polymer, etc., and it is very beneficial for promoting growth when humans or animals ingest liquid or dried product of the culture, and it is traditionally safe bacteria or culture.

다음으로, 가시오가피는 오가과(Araliaceae)에 속한 낙옆관목인 자오가 Acanthopanax senticosus (RUPR. et MAXIM) HARMS의 뿌리와 근경 및 수피를 건조한 것으로 카로텐(carotene), 리구스트린(ligustrin), 7-메틸-6,8-디메틸쿠마린글리코 사이드(7-methyl- 6,8-dimethylcoumarineglycoside), 갈락토사이드(galactoside), 시린가레시놀 디-O-베타-D-글루코사이드(syringaresinol di-o-beta-D-glucoside) 및 카리오피fp놀(caryophyllenol) 등의 여러 가지 배당체와 클로로제닉 에시드(chlorogenic acid), 플라본(flavone), 정유, 다당 등이 함유되어 있다.Next, prickly oleracea is a deciduous shrub belonging to the Araliaceae, and the dried roots, rhizomes, and bark of Acanthopanax senticosus (RUPR. Et MAXIM) HARMS are carotene, ligustrin, 7-methyl- 6,8-dimethylcoumaringlycoside, galactoside, syringaresinol di-o-beta-D-glucoside ) And various glycosides such as caryophyllenol, chlorogenic acid, flavone, essential oil and polysaccharide.

그리고, 홍화씨는 뼈를 강화시키며 근골을 튼튼히 하는데 효과를 지닌다.And, safflower seeds are effective in strengthening bones and strengthening the muscles.

산약은 건비(健脾), 보폐(補肺), 고신(固腎), 익정(益精)의 효능으로 비허설사, 오래된 설사, 허로해수, 소갈, 유정, 대하, 소변빈삭 증상을 치료하는데 상용되는 한약으로 주성분으로 사포닌(saponin), 점액, 콜린(cholin), 전분, 글라이코프로테인(glycoprotein), 유리아미노산 등이 함유되어 있다.The medicine is used to treat the symptoms of non-herb diarrhea, old diarrhea, seawater, small salt, oil well, lobster, urine binsak, with the efficacy of dry rain, abolism, high body, and Ikjeong. The main ingredient is saponin, mucus, choline, starch, glycoprotein, and free amino acid.

산수유는 보익간신(補益肝腎), 삽정고탈(澁精固脫)의 효능으로 현훈, 이명, 요슬산통, 양위유정, 유뇨, 뇨의빈삭, 붕루대하 등 증상을 치료하는데 상용되는 한약으로 코닌(cornin), 베르베날린(verbenalin), 사포닌(saponin), 탄닌(tannin), 우르소산(ursolic acid), 사과산, 주석산 등 성분이 함유되어 있다.Cornus is a Chinese medicine commonly used to treat symptoms such as Hyun-hoon, Tinnitus, Yoshinan colic, Urinary well, Urinary tract, Urinary tract, and Bubodae, due to the efficacy of Boik Ganshin and eclampsia. Cornin, verbenalin (verbenalin), saponin (saponin), tannin (tannin), ursolic acid (ursolic acid), malic acid, tartaric acid and other ingredients are contained.

복령은 이수삼습(利水渗濕), 건비녕심(健脾寧心)의 효능으로 수종뇨소, 담음현훈, 비허식소, 변당설사, 심신불안 등 증상을 치료하는데 상용되어온 한약으로 주성분은 베타-패시만(β-pacyman)이 7.5 중량% 함유되어 있고, 또 트리터페노이드(triterpenoid) 화합물인 패시믹산(pachymic acid), 에브리코익산(ebricoic acid), 튜무로식산(tumulosic acid), 피니코릭산(pinicolic acid) 등이 함유되어 있다.Bokryeong is an herbal medicine that has been commonly used to treat symptoms such as water urinary tract, Damdam Hyeon-hoon, unhavened place, diarrhea, and mental and anxiety with the efficacy of Isu Samsu and Geunbinyeongsim. 7.5 wt% of β-pacyman and triterpenoid compounds, pachymic acid, ebricoic acid, tumulosic acid, and pinicoric acid ( pinicolic acid).

녹각은 온신양(溫腎陽), 강근골(强筋骨), 행혈소종(行血消腫)의 효능으로 양 위유정, 요슬관절이 시리고 아플 때 상용되어온 한약으로 주성분은 교질과, 인산칼슘, 탄산칼슘 등이 있다.Green rust is a herb that has been commonly used when both stomach oil and knee joints are cold and ill due to the efficacy of Onsinyang, Kang Geungol, and hemangioma. The main components are colloid, calcium phosphate, Calcium carbonate and the like.

인삼은 대보원기(大補元氣), 고탈생진(固脫生津), 안신(安神)의 효능으로 과로로 인한 허로증상, 식사량감소, 무기력증, 건망증, 양위증, 소갈증 등에 사용하는 한약으로 주성분은 사포닌 성분과, 베타엘레멘(β-elemen), 팔미틴산(palmitin acid), 스테아린산(stearin acid), 올레인산(olein acid), 리놀산(linol acid) 등의 인삼산과 콜린(cholin), 단백류, 다당류 등이 함유되어 있다.Ginseng is a herbal medicine used for the symptoms of overwork, reduced meals, lethargy, forgetfulness, gastritis, and thirst due to the effects of Daebowongi, Gotalengjin, and Anshin. Ingredients, beta-elemen, palmitic acid, stearic acid, olein acid, olein acid, linol acid, and other ginseng acids such as cholin, protein, and polysaccharides It is contained.

이하, 가시오가피와 상기 6종 한약재의 혼합물로부터 한약 추출물을 제조하는 방법에 대하여 설명한다.Hereinafter, a method of preparing a Chinese herbal extract from the mixture of thorn ogapi and the six herbal medicines will be described.

우선, 전체 혼합물을 기준으로 가시오가피 10-90 중량%, 홍화씨 0.1-50 중량%, 산약 0.1-50 중량%, 산수유 0.1-50 중량%, 복령 0.1-50 중량%, 녹각 0.1-50 중량%, 인삼 0.1-50 중량%가 되도록 칭량한 후 이를 추출 탱크에 투입한다.First of all, 10-90% by weight, 0.1-50% by weight safflower, 0.1-50% by weight, 0.1-50% by weight of cornus oil, 0.1-50% by weight of fuxing, 0.1-50% by weight of green tea, ginseng Weigh to 0.1-50% by weight and place it in the extraction tank.

다음으로, 원료 총 합계의 2-20 배(W/V)에 해당하는 20-100% 주정 수용액(메탄올, 에탄올, 또는 부탄올), 에틸아세테이트 또는 물을 추출용매로 사용하여 상온에서 1-24시간 동안 침적시킨 다음 8-12시간 동안 추출하게 된다. 이때 추출온도는 20-100% 주정수용액 또는 에틸아세테이트를 사용한 경우에는 60-80℃가 바람직하며, 물을 이용한 추출일 경우 90℃-100℃가 바람직하다. Next, 1-24 hours at room temperature using 20-100% alcohol solution (methanol, ethanol or butanol), ethyl acetate or water as an extractant, which is 2-20 times (W / V) of the total raw materials. And then extracted for 8-12 hours. In this case, the extraction temperature is preferably 60-80 ° C. when 20-100% alcohol solution or ethyl acetate is used, and 90 ° C.-100 ° C. when the extraction is performed using water.

상기 추출이 끝난 후, 1차로 투입되어 있는 한약재를 제거하고 남은 여액을 마이크로필터(Micro filter) 또는 필터 프레스(Filter Press)를 사용하여 추출용매에 잔존하는 찌꺼기 등 불용성 물질들을 제거시킨 다음, 분리된 추출액을 감압농축 기를 이용하여 고형분 농도가 60-70 중량%가 되도록 농축시킨다.After the extraction is completed, the first step is to remove the medicinal herbs and the remaining filtrate using a micro filter (Filter) or a filter press (Filter Press) to remove insoluble substances such as residues remaining in the extraction solvent, and then separated The extract is concentrated using a reduced pressure concentrator so that the solid concentration is 60-70% by weight.

마지막으로, 상기 제조된 농축액을 동결건조기를 이용하여 동결 건조하고 분쇄하여 분말의 성상으로 제조하는데, 이때 동결 건조된 추출물 분말의 수득율은 추출공정 초기에 투입된 한약재 중량의 5-20%(W/W)가 되는 것이 바람직하다.Finally, the prepared concentrate is freeze-dried using a lyophilizer and pulverized to prepare a powder. The yield of the freeze-dried extract powder is 5-20% (W / W) of the weight of the herbal medicine added at the beginning of the extraction process. It is preferable to become).

그러나, 상기 한약재 추출물 추출과정은 통상의 초음파 추출법, 여과법, 환류 추출 또는 감압농축법이 사용될 수 있으며, 이 밖에도 통상적으로 사용되는 추출법이 사용될 수 있으며, 농축 및 동결과정 역시 통상적으로 알려진 방법이 다양하게 사용될 수 있다. However, the herbal extract extraction process may be used conventional ultrasonic extraction, filtration, reflux extraction or reduced pressure concentration method, in addition to the conventional extraction method may be used, concentration and freezing process is also a variety of commonly known methods Can be used.

또한, 상기의 추출물은 이후 제조될 제품의 제형(분말, 정제, 액상 등의 타입)에 따라 농축액, 추출액, 동결 건조 분말의 형태로 응용 가능하다.In addition, the extract may be applied in the form of concentrate, extract, freeze-dried powder, depending on the formulation of the product to be prepared (type of powder, tablet, liquid, etc.).

다음으로, 바실러스 배양물의 제조방법에 대하여 설명한다.Next, the manufacturing method of a Bacillus culture is demonstrated.

상기 바실러스 배양물은 멸균된 배지에서 배양된다. 상기 배지는 통상의 배지가 사용될 수 있으며, 바람직하게는 전체 배지 성분 중 옥수수전분 등의 탄수화물 성분 0.5 내지 5 중량%, 대두분 등의 단백질 성분 0.2 내지 2 중량%, 효모추출물 0.2 내지 0.7 중량%, 인산칼륨 등의 인산 성분 0.05 내지 0.2 중량%가 포함되어 함유할 수 있다. 상기 배지에 바실러스 서브틸리스 모리(Bacillus subtilis MORI)균을 접종한 다음 30 내지 45℃에서 2 ~ 5일간 0.05 내지 0.4 vvm(vol/vol/min.)의 통기량과 교반속도 100 내지 200 rpm(rotary/min.), 내압 0.1 내지 1 kgf/㎠으로 배양할 수 있다. 상기 배지의 pH는 6.0 내지 9.0 일 수 있다. 상기 배양된 바실러스 배양액은 원심분리기에서 원심분리한 다음 5 내지 15배 농축하여 3 내지 7배의 탄산칼슘이나 덱스트린(dextrin)에 흡착하여 건조시키는 것이 바람직하다.The Bacillus culture is cultured in sterile medium. The medium may be a conventional medium, preferably 0.5 to 5% by weight of carbohydrate components such as corn starch, 0.2 to 2% by weight of protein components such as soy flour, 0.2 to 0.7% by weight of yeast extract, 0.05 to 0.2% by weight of a phosphoric acid component such as potassium phosphate may be contained. After inoculating Bacillus subtilis MORI bacteria to the medium, the aeration amount and stirring speed of 0.05 to 0.4 vvm (vol / vol / min.) For 2 to 5 days at 30 to 45 ° C and agitation speed of 100 to 200 rpm ( rotary / min.), and may be incubated at an internal pressure of 0.1 to 1 kgf / cm 2. The pH of the medium may be 6.0 to 9.0. The cultured Bacillus culture is preferably centrifuged in a centrifuge and then concentrated by 5 to 15 times and dried by adsorbing to 3 to 7 times calcium carbonate or dextrin.

마지막으로, 상기 제조된 한약재 추출물과 상기 바실러스 배양물을 혼합하여, 최종 조성물의 함량이 한약 추출물 100 중량부 및 바실러스 배양물 0.1-10 중량부가 되도록 한다.Finally, the prepared herbal extract and the Bacillus culture are mixed, so that the content of the final composition is 100 parts by weight of the herbal extract and 0.1-10 parts by weight of the Bacillus culture.

이하, 실시예를 통하여, 본 발명을 보다 구체적으로 설명한다. 그러나 하기 실시예는 본 발명을 예시하는 것일 뿐이며, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.

<< 제조예Production Example 1> 가시오가피 및 6종 한약재 추출물 제조 1> Preparation of Prickly Pear and Six Herbal Medicine Extracts

가시오가피와 6종 한약재 혼합물(가시오가피 50 중량%, 홍화씨 14 중량%, 산약 6.5 중량%, 산수유 6.5 중량%, 복령 10 중량%, 녹각 6.5 중량%, 인삼 6.5 중량%)을 원료 총 중량에 10배(w/v)에 해당하는 50%(v/v) 주정수용액을 추출용매로 사용하여 1시간동안 침적시킨다. 50℃로 유지하면서 5시간 동안 초음파로 추출한 뒤, 70℃에서 overnight(10시간)하여 추출이 끝난 후, 상등액을 마이크로필터로 여과하였다. 여과된 추출물을 고형분 농도가 65 중량%가 되도록 농축하였다. 농축액을 동결건조기로 건조하고 분쇄하여 분말의 성상을 제조하였다. 동결건조 후 초기 투입된 한약재 중량의 10%(w/w)이상 수득하도록 하였다.10 times the total weight of the raw material (50% by weight of shiogapi, 14% by weight of safflower seed, 6.5% by weight of acidic acid, 6.5% by weight of cornus oil, 10% by weight of Fukryeong, 6.5% by weight of green tea, 6.5% by weight of ginseng) 50% (v / v) drinking water solution corresponding to w / v) was used as an extraction solvent and soaked for 1 hour. Ultrasonic extraction for 5 hours while maintaining at 50 ℃, overnight extraction (10 hours) at 70 ℃ after the extraction, the supernatant was filtered through a micro filter. The filtered extract was concentrated to a solid concentration of 65% by weight. The concentrate was dried with a lyophilizer and ground to prepare a powder. After lyophilization, more than 10% (w / w) of the weight of the initially added herbal medicine was obtained.

<< 제조예Production Example 2>  2> 바실러스Bacillus 배양물의 제조 Preparation of Culture

바실러스 서브틸리스 모리(Bacillus subtilis MORI KCCM 10450)균을 옥수수전분 2중량%, 대두분 1.0중량%, 효모추출물 0.5중량%, 제1인산칼륨 0.1중량%, 소포제 0.02중량%가 함유한 배지(pH 7.5)에 접종하여 250rpm, 37-38℃, 통기량 0.3vvm 조건에서 3일간 배양한 다음 탄산칼슘을 배양된 배지 중량의 10%로 넣은 후 잘 교반하면서 투입(inlet)온도 120℃, 출구(outlet)온도 85℃의 조건으로 분사 건조하여 바실러스 배양물을 제조하였다. Bacillus subtilis MORI KCCM 10450 is a medium containing 2% by weight of corn starch, 1.0% by weight of soy flour, 0.5% by weight of yeast extract, 0.1% by weight of potassium monophosphate, and 0.02% by weight of antifoaming agent (pH). 7.5) and incubated for 3 days at 250rpm, 37-38 ℃, aeration 0.3vvm conditions, and then put calcium carbonate at 10% of the culture medium weight and stirred well inlet temperature 120 ℃, outlet (outlet) Bacillus cultures were prepared by spray drying at a temperature of 85 ° C.

<< 제조예Production Example 3> 유산균 배양물의 제조 3> Preparation of Lactic Acid Bacteria Culture

락토바실러스 헬베티쿠스(Lactobacillus helveticus) 균은 펩톤 1중량%, 고기추출물 1 중량%, 효모 추출물 0.5 중량%, 포도당 2 중량%, 소르비탄모노올레이트 0.01%, 구연산암모늄 0.5%, 초산나트륨 0.01%, 황산마그네슘 0.01%, 황산망간 0.005%, 제2인산칼륨 0.2%의 배지(pH 6.5)에 접종하여 37℃에서 3일간 120rpm으로 진탕 배양한 다음 8,000rpm에서 원심분리하여 락토바실러스만 얻은 뒤 원물 중량의 30%에 해당하는 스킴밀크(skim milk)를 넣은 후 동결 건조하여 제조하였다. Lactobacillus helveticus ) bacteria 1% by weight peptone, 1% by weight meat extract, 0.5% by weight yeast extract, 2% by weight glucose, sorbitan monooleate 0.01%, ammonium citrate 0.5%, sodium acetate 0.01%, magnesium sulfate 0.01%, sulfate Inoculate in medium of 0.005% manganese and 0.2% potassium diphosphate (pH 6.5), shake culture at 120rpm for 3 days at 37 ℃, centrifuge at 8,000rpm to obtain only Lactobacillus, and 30% of the original weight. After putting milk (skim milk) was prepared by freeze drying.

[[ 실험예Experimental Example ]]

하기 실시예 1 내지 2는 SD계 수컷 흰쥐(3주령)를 구입(샘타코, 대한민국)하여 이를 대상으로 5일간 온도 22℃, 습도 50% 및 주야 12시간으로 조절하여 동물실험실에서 적응시킨 것이다. 총 시험기간은 2주로 하였으며, 체중과 사료섭취량은 매일 1회 측정하였다.In Examples 1 to 2, SD male rats (3 weeks old) were purchased (Samtaco, South Korea) and adjusted to an animal laboratory by adjusting the temperature to 22 ° C., 50% humidity, and 12 hours of day and night for 5 days. The total test period was 2 weeks, and body weight and feed intake were measured once daily.

<< 실험예Experimental Example 1> 성장촉진 효능시험 1> Growth Promotion Test

동일한 연령, 성별의 SD rat을 사용하여 각 시험구를 5마리로 구성하였다. 아래표와 같이 시험구를 1)대조구(식염수만 투여), 2)가시오가피와 상기 6종 한약재의 혼합구, 3)가시오가피와 상기 6종 한약재와 바실러스 배양물의 혼합구, 4)가시오가피와 6종 한약재와 상기 유산균 배양물의 혼합구, 5)가시오가피와 6종 한약 재에 계면활성제(Sorbitan monooleate)의 처리한 혼합구, 6)가시오가피와 6종 한약재, 상기 유산균 배양물과 상기 바실러스 배양물에 계면활성제를 처리한 혼합구로 나누어 아래 표3과 같이 실시하였다. 그 결과 3)가시오가피와 상기 6종 한약재와 바실러스 배양물의 혼합구에 대한 체중증가율이 가장 우수하였으며(도 1 참조), 혈청내 IGF-1의 함량의 경우는 모든 시험구가 대조구보다 우수하게 나타났으며, 특히 6)가시오가피와 6종 한약재와 유산균 배양물 및 바실러스 배양물에 계면활성제를 처리한 혼합구가 유의성 있게 가장 높게 나타났다(표 4 참조). 또한, 가시오가피와 6종 한약재에 바실러스 배양물 혼합구의 성숙부 길이가 유의적으로 길게 나타났다(표 5 참조).  Each test group was composed of SD rats of the same age and sex. As shown in the table below, 1) control (administration of saline only), 2) mixed squid and 6 kinds of herbal medicine, 3) mixed squid and 6 kinds of herbal medicine and Bacillus culture, 4) squid and 6 kinds of herbal medicine And a mixture of the lactic acid bacteria cultures, 5) a mixture of treated with a surfactant (Sorbitan monooleate) in the Gasiogapi and six kinds of herbal medicines, 6) a mixture of Gasiogapi and six herbs, the surfactant in the lactic acid cultures and the Bacillus culture The mixture was divided into treated spheres and performed as Table 3 below. As a result, 3) the weight gain rate was the highest in the mixed diets of psigapi and the six medicinal herbs and Bacillus cultures (see FIG. 1). In the case of serum IGF-1 content, all the test groups were better than the control group. Especially, the mixture treated with surfactant was the highest in Gasiogapi, six herbs, lactic acid bacteria cultures and Bacillus cultures (see Table 4). In addition, the maturation length of the Bacillus culture mixture was shown to be significantly longer in the thorn stem and 6 kinds of Chinese herbal medicine (see Table 5).

*[표 1]* [Table 1]

시험구Test 투여용량Dosage 장골길이 (mm)Long bone length (mm) 장골상부 폭(mm)Upper iliac width (mm) 장골중간폭 (mm)Long bone medium width (mm) 장골하부폭 (mm)Lower iliac width (mm) 장골무게 (mg)Iliac weight (mg) 대조구(식염수)Control (saline) 100 mg/kg100 mg / kg 27.72 ±0.8027.72 ± 0.80 6.10±0.086.10 ± 0.08 2.42±0.072.42 ± 0.07 3.49±0.053.49 ± 0.05 265±9.26265 ± 9.26 가시오가피와 6종 한약재 Gogagapi and 6 kinds of herbal medicine 100 mg/kg100 mg / kg 28.11 ±0.2528.11 ± 0.25 6.12±0.086.12 ± 0.08 2.40±0.062.40 ± 0.06 3.46±0.053.46 ± 0.05 262±8.38262 ± 8.38 가시오가피와 6종 한약재, 바실러스 배양물Ogapi and 6 Herbs, Bacillus Culture 100 mg/kg 5mg/kg100 mg / kg 5mg / kg 28.39 ±0.2028.39 ± 0.20 6.03±0.066.03 ± 0.06 2.26±0.052.26 ± 0.05 3.50±0.043.50 ± 0.04 260±5.69260 ± 5.69 가시오가피와 6종 한약재, 유산균 배양물Ogapi and 6 Herbs, Lactic Acid Bacteria Culture 100 mg/kg 5 mg/kg100 mg / kg 5 mg / kg 28.14 ±0.2528.14 ± 0.25 6.05±0.046.05 ± 0.04 2.33±0.072.33 ± 0.07 3.40±0.053.40 ± 0.05 255±7.73255 ± 7.73 가시오가피와 6종 한약재, 계면활성제Prickly Pear and 6 Herbs, Surfactants 100 mg/kg 5 mg/kg100 mg / kg 5 mg / kg 28.44 ±0.2428.44 ± 0.24 6.26±0.106.26 ± 0.10 2.33±0.062.33 ± 0.06 3.57±0.04*3.57 ± 0.04 * 259±8.47259 ± 8.47 가시오가피와 6종 한약재, 계면활성제, 유산균 배양물, 바실러스 배양물Prickly Pear and Six Herbs, Surfactants, Lactic Acid Bacteria Culture, Bacillus Culture 100 mg/kg 5 mg/kg, 5 mg/kg, 5 mg/kg100 mg / kg 5 mg / kg, 5 mg / kg, 5 mg / kg 27.99 ±0.1827.99 ± 0.18 5.91±0.075.91 ± 0.07 2.20±0.042.20 ± 0.04 3.37±0.043.37 ± 0.04 255±6.82255 ± 6.82

*; p<0.05*; p <0.05

상기 장골 생육 측정방법은 각 시험구을 2주간 경구투여한 실험동물 SD rat를 ether로 마취시킨 후, 좌우 장골을 분리하여 캘리퍼스를 이용하여 총길이, 폭(상부, 중부, 하부) 및 무게를 측정하였다.The method of measuring iliac growth was anesthetized with experimental rat SD rats orally administered for two weeks, and then, the left and right iliac bones were separated, and total length, width (upper, middle, lower) and weight were measured using calipers.

[표 2]TABLE 2

시험구Test IGF-1(ng/ml)IGF-1 (ng / ml) 대조구 Control 1508±91508 ± 9 가시오가피와 6종 한약재  Gogagapi and 6 kinds of herbal medicine 1530±61530 ± 6 가시오가피와 6종 한약재, 바실러스 배양물 Ogapi and 6 Herbs, Bacillus Culture 1677±71677 ± 7 가시오가피와 6종 한약재, 유산균 배양물 Ogapi and 6 Herbs, Lactic Acid Bacteria Culture 1613±11613 ± 1 가시오가피와 6종 한약재, 계면활성제 Prickly Pear and 6 Herbs, Surfactants 1565±31565 ± 3 가시오가피와 6종 한약재, 계면활성제, 유산균 배양물, 바실러스 배양물 Prickly Pear and Six Herbs, Surfactants, Lactic Acid Bacteria Culture, Bacillus Culture 1819±23*1819 ± 23 *

*; p<0.05*; p <0.05

상기 혈액내 IGF-1 분석방법은 각 시험구를 2주간 경구투여한 실험동물 SD rat를 ether로 마취시킨 후, 1 ml이상 안와채혈하여 혈액응고촉진튜브(BD vacutainer, 미국)에 담고 원심분리하여 혈청을 분리하였다. 분리된 혈청내 IGF-1 함량을 OCTEIA Rat/Mouse IGF-1 kit(IDS; Immunodiagnostic systems, UK)를 이용하여 측정하였다.In the blood IGF-1 analysis method, anesthetized the experimental animals SD rats administered orally for 2 weeks with ether, followed by orbital collection for 1 ml or more in a blood coagulation tube (BD vacutainer, USA) and centrifuged. Serum was isolated. The serum IGF-1 content was measured using the OCTEIA®Rat / Mouse IGF-1 kit (IDS; Immunodiagnostic systems, UK).

[표 3]TABLE 3

시험구Test 휴지부Rest 증식부Growth 성숙부Mature 비대부Hypertrophy 대조구 Control 48.7±2.348.7 ± 2.3 136.7±6.1136.7 ± 6.1 153.1±6.3153.1 ± 6.3 295.9±5.2295.9 ± 5.2 가시오가피와 6종 한약재  Gogagapi and 6 kinds of herbal medicine 48.2±2.648.2 ± 2.6 116.8±3.5116.8 ± 3.5 152.3±4.8152.3 ± 4.8 285.9±5.4285.9 ± 5.4 가시오가피와 6종 한약재, 바실러스 배양물 Ogapi and 6 Herbs, Bacillus Culture 45.3±2.745.3 ± 2.7 116.0±3.2116.0 ± 3.2 183.2±5.0*183.2 ± 5.0 * 272.7±5.4272.7 ± 5.4 가시오가피와 6종 한약재, 유산균 배양물 Ogapi and 6 Herbs, Lactic Acid Bacteria Culture 53.9±2.4*53.9 ± 2.4 * 110.3±4.3110.3 ± 4.3 162.6±7.7162.6 ± 7.7 285.2±7.2285.2 ± 7.2 가시오가피와 6종 한약재, 계면활성제 Prickly Pear and 6 Herbs, Surfactants 43.4±1.543.4 ± 1.5 108.4±2.8108.4 ± 2.8 157.7±4.3157.7 ± 4.3 311.3±6.4311.3 ± 6.4 가시오가피와 6종 한약재, 계면활성제, 유산균 배양물, 바실러스 배양물 Prickly Pear and Six Herbs, Surfactants, Lactic Acid Bacteria Culture, Bacillus Culture 47.9±2.347.9 ± 2.3 138.5±6.9138.5 ± 6.9 159.3±4.9159.3 ± 4.9 295.9±5.2295.9 ± 5.2

*; p<0.05*; p <0.05

<< 실험예Experimental Example 2> 기존제품과 개선된 제품의 성장촉진 효능시험 2> Growth promotion efficacy test of existing and improved products

각 시험구로서, 실험예 1과 동일한 연령, 성별의 SD rat을 정상 체중쥐(초기 체중 70~80 g이상) 5마리, 저 체중쥐(초기체중 30~40g) 3마리, 총 8마리로 구성하였으며, 사료의 섭취를 충분히 시키기 위하여 다른 케이지에 나누어 시험하였다.In each test group, SD rats of the same age and sex as Experimental Example 1 consisted of 5 normal weight mice (initial weight of 70 to 80 g or more), 3 low weight mice (initial weight of 30 to 40 g), and 8 in total. The test was divided into different cages for sufficient feed intake.

대조구를 제외한 모든 시험구에 기존 제품(상품명 Kicker, 파진바이오사, 주요성분 - 숙지황, 산약, 산수유, 복령, 녹각 및 인삼의 추출물 50 중량%, 유당 20 중량%, 해조칼슘 15 중량%, 코코아분말 7 중량%, 자일리톨 5 중량%, 클로렐라 2 중량%, 맥주효모 1 중량%, 수크랄로스 0.02 중량%)와 가시오가피와 6종 한약재를 각각 쥐 체중 ㎏당 100 mg/kg 되도록 첨가하였다. 다음으로, 개선 1구에는 바실러스 배양물 10 mg/kg 첨가하고, 개선 2구에는 비타민 AD3, SFT-65를 각각 4mg/kg, 0.1mg/㎏씩 첨가하고, 개선 3구는 바실러스 배양물, 비타민 AD3, SFT-65(polyethylene sorbitan monostearate)를 각각 10mg/kg, 4mg/kg, 0.1mg/kg씩 첨 가하여 아래 표 4과 같이 실시하였다. 그 결과 저체중의 쥐의 경우 개선1구가 사료섭취량도 우수하였고, 체중증가율이 뚜렷하게 우수하였다(도 2 및 표 5 참조).Existing products (trade name Kicker, fazin biosa, main ingredients-50% by weight of extracts of Sookji, acid, cornus, bokyeong, green and ginseng, 20% by weight lactose, 15% by weight seaweed calcium, cocoa powder 7% by weight, 5% by weight of xylitol, 2% by weight of chlorella, 1% by weight of brewer's yeast, 0.02% by weight of sucralose) and thorny scabies and six Chinese herbs were added to 100 mg / kg per kg of rat body weight, respectively. Next, 10 mg / kg of Bacillus culture was added to the first round of improvement, and 4 mg / kg and 0.1 mg / kg of vitamin AD3 and SFT-65 were respectively added to the second round of improvement, and the third round of the Bacillus culture and vitamin AD3 was added. , SFT-65 (polyethylene sorbitan monostearate ) was added to 10mg / kg, 4mg / kg, 0.1mg / kg, respectively, as shown in Table 4 below. As a result, the low-weight rats showed better feed intake and improved weight gain significantly (see FIG. 2 and Table 5).

[표 4]TABLE 4

<정상 체중 쥐 대상><Normal weight rat target>

투여용량 (mg/kg)Dosage (mg / kg) 장골길이 (mm)Long bone length (mm) 장골상부폭 (mm)Upper iliac width (mm) 장골중간폭 (mm)Long bone medium width (mm) 장골하부폭 (mm)Lower iliac width (mm) 장골무게 (mg)Iliac weight (mg) 대구식염수 100 Cod saline 100 29.98±0.15 29.98 ± 0.15 6.54±0.07 6.54 ± 0.07 2.41±0.04 2.41 ± 0.04 3.65±0.05 3.65 ± 0.05 318±4.58 318 ± 4.58 Kicker 100, 가시오가피+ 6종한약재 100Kicker 100, Prickly Pear + 6 Herbs 100 30.45±0.25 30.45 ± 0.25 6.43±0.09 6.43 ± 0.09 2.47±0.07 2.47 ± 0.07 3.64±0.06 3.64 ± 0.06 324±12.13 324 ± 12.13 Kicker 100, 가시오가피+ 6종한약재 100 바실러스 배양물 10Kicker 100, Prickly Pear + 6 Herbs 100 Bacillus Cultures 10 30.16±0.13 30.16 ± 0.13 6.37±0.03 6.37 ± 0.03 2.42±0.06 2.42 ± 0.06 3.69±0.03 3.69 ± 0.03 328±3.84 328 ± 3.84 Kicker 100, 가시오가피+ 6종한약재 100, AD3 4, SFT-65 0.1,Kicker 100, Prickly Pear + 6 Herbs 100, AD3 4, SFT-65 0.1, 30.34±0.09  30.34 ± 0.09 6.38±0.06  6.38 ± 0.06 2.34±0.04  2.34 ± 0.04 3.54±0.04  3.54 ± 0.04 322±6.41  322 ± 6.41 Kicker 100, 가시오가피+ 6종한약재 100, 바실러스 배양물 10, AD3 4, SFT-65 0.1Kicker 100, Viscera + 6 Herbs 100, Bacillus Culture 10, AD3 4, SFT-65 0.1 29.88±0.15  29.88 ± 0.15 6.22±0.08  6.22 ± 0.08 2.95±0.04  2.95 ± 0.04 3.53±0.05  3.53 ± 0.05 298±7.03  298 ± 7.03

[표 5]TABLE 5

<저체중 쥐 대상><Underweight rat subject>

시험구Test 투여용량 (mg/kg)Dosage (mg / kg) 장골길이 (mm)Long bone length (mm) 장골상부 폭(mm)Upper iliac width (mm) 장골중간폭 (mm)Long bone medium width (mm) 장골하부폭 (mm)Lower iliac width (mm) 장골무게 (mg)Iliac weight (mg) 대조구  Control 식염수 Saline 27.80±0.12 27.80 ± 0.12 6.13±0.04 6.13 ± 0.04 2.40±0.06 2.40 ± 0.06 3.70±0.03 3.70 ± 0.03 270±4.82 270 ± 4.82 기존 existing Kicker 100, 가시오가피 + 6종한약재 100Kicker 100, Prickly Pear + 6 Herbs 100 28.52 ±0.31* 28.52 ± 0.31 * 6.16±0.05 6.16 ± 0.05 2.47±0.06 2.47 ± 0.06 3.56±0.03 3.56 ± 0.03 286±4.87 286 ± 4.87 개선 1  Improvement 1 Kicker 100, 가시오가피 + 6종한약재 100, 바실러스 배양물10Kicker 100, Prickly Pear + 6 Herbs 100, Bacillus Cultures 10 28.33 ±0.04* 28.33 ± 0.04 * 6.30±0.09 6.30 ± 0.09 2.32±0.04 2.32 ± 0.04 3.62±0.06 3.62 ± 0.06 279±6.45 279 ± 6.45 개선 2  Improvement 2 Kicker 100, 가시오가피 + 6종한약재 100, AD3 4, SFT-65 0.1,Kicker 100, Viscera + 6 Herbs 100, AD3 4, SFT-65 0.1, 27.82±0.15  27.82 ± 0.15 6.05±0.04  6.05 ± 0.04 2.26±0.06  2.26 ± 0.06 3.35±0.17  3.35 ± 0.17 258±4.83  258 ± 4.83 개선 3   Improvement 3 Kicker 100, 가시오가피 + 6종한약재 100, 바실러스 배양물 10, AD3 4, SFT-65 0.1Kicker 100, Viscera + 6 Herbs 100, Bacillus Culture 10, AD3 4, SFT-65 0.1 28.46 ±0.14*  28.46 ± 0.14 * 6.25±0.09  6.25 ± 0.09 2.45±0.08  2.45 ± 0.08 3.64±0.03   3.64 ± 0.03 287±6.77*  287 ± 6.77 *

*; p<0.05*; p <0.05

IGF-1의 시험결과는 저체중 쥐에서 개선 1이 가장 유의성이 있게 높게 측정되었다(표 7, 도 3 참조).The test results of IGF-1 were measured that improvement 1 was most significantly higher in underweight mice (see Table 7, Figure 3).

[표 6]TABLE 6

<정상 체중 쥐 대상><Normal weight rat target>

시험구명Test Life IGF-1(ng/ml)IGF-1 (ng / ml) 대조구Control 1398±1151398 ± 115 기존existing 1415±561415 ± 56 개선1Improvement 1 1645±59*1645 ± 59 * 개선2Improvement 2 1652±45*1652 ± 45 * 개선3Improvement 3 1511±481511 ± 48

*; p<0.05*; p <0.05

[표 7]TABLE 7

<저체중 쥐 대상><Underweight rat subject>

시험구명Test Life IGF-1(ng/ml)IGF-1 (ng / ml) 대조구Control 1249±471249 ± 47 기존existing 1272±171272 ± 17 개선1Improvement 1 1616±55* 1616 ± 55 * 개선2Improvement 2 1511±67* 1511 ± 67 * 개선3Improvement 3 1497±18* 1497 ± 18 *

*; p<0.05*; p <0.05

다음은 본 발명을 건조 형태 또는 액상 형태에 따라 제조한 것이다.The following is to prepare the present invention according to the dry form or liquid form.

<< 실시예Example 1> 1>

가시오가피 75 중량%, 홍화씨 7 중량%, 복령 5 중량%, 산악 3.25 중량%, 녹각 3.25 중량%, 인삼 3.25 중량%, 및 산수유 3.25 중량%를 포함하는 혼합물로부터 추출된 한약 추출물 50 중량%, 유당 20 중량%, 해조칼슘 15 중량%, 코코아 분말 7 중량%, 자일리톨 5 중량%, 바실러스 배양물 3 중량%를 혼합하여 성장촉진 효과가 있는 건조형태의 약제 조성물을 완성하였다.   50% by weight herbal extract extracted from a mixture comprising 75% by weight of barberry, 7% by weight of safflower seed, 5% by weight of Bokryeong, 3.25% by weight of mountain green, 3.25% by weight of green tea, 3.25% by weight of ginseng, and 3.25% by weight of cornus oil, lactose 20 Wt%, algae calcium 15%, cocoa powder 7% by weight, xylitol 5% by weight, Bacillus culture 3% by weight was mixed to complete the dry pharmaceutical composition having a growth promoting effect.

<< 실시예Example 2>  2>

가시오가피 추출액 50.5 중량%, 홍화씨 추출액 14 중량%, 복령 추출액 10 중량%, 산약 추출액 6.5 중량%, 녹각 추출액 6.5 중량%, 인삼 추출액 6.5 중량%, 및 산수유 추출액 6 중량%을 포함하는 혼합물로부터 추출된 한약 추출물 10중량%, 바실러스 배양물 0.5 중량%, 벌꿀 69 중량%, 자몽종자 추출액 0.2 중량%, 사과향 0.3 중량%, 카르복시메틸셀룰로오즈나트륨 20 중량%를 혼합한 다음 폴리프로필렌 수지로된 포장재에 충진하여 액상 형태의 성장촉진 효과가 있는 약제 조성물을 완성하였다.  Herbal medicine extracted from a mixture comprising 50.5% by weight of Prickly Pear Extract, 14% by weight of Safflower Seed Extract, 10% by weight of Bokryeong Extract, 6.5% by weight Poach Extract, 6.5% by weight Green Extract, 6.5% by weight of Ginseng Extract, and 6% by weight of Cornus Extract 10% by weight of the extract, 0.5% by weight of Bacillus culture, 69% by weight of honey, 0.2% by weight of grapefruit seed extract, 0.3% by weight of apple flavor, 20% by weight of sodium carboxymethylcellulose, and then filled into a polypropylene resin packing liquid A pharmaceutical composition having a growth promoting effect in form was completed.

<< 실시예Example 3> 3>

실시예 1의 조성물에 상기 조성물의 1 중량%인 CMC-Na와 0.5 중량%의 사과향, 0.3 중량%의 비타민 C를 추가로 더 혼합한 다음 타정기로 타정하여 성장촉진 효과가 있는 건조형태의 정제형태의 조성물을 완성하였다.   The composition of Example 1 is further mixed with 1% by weight of CMC-Na and 0.5% by weight of apple flavor, 0.3% by weight of vitamin C and then tableting with a tableting machine in a dry form having a growth promoting effect The composition of was completed.

본 발명의 성장 활성물질인 가시오가피 및 6종 한약재의 한약추출물과 바실러스 배양물을 함유함으로써 성장촉진이 더욱 개선될 수 있는 효과를 가지는바, 정상적인 성장을 하는 유년-사춘기의 성장 단계시기에 성장을 촉진시킬 수 있을 뿐만 아니라 소인증, 왜소증 및 소아의 발육부진과 성장저하 등 성장 장애 관련 질환의 치료 및 예방 효과를 가진다.By containing the growth active material of the present invention, the thorny opiaceae and the six herbal medicine extracts and Bacillus cultures have the effect that the growth promotion can be further improved, promote the growth during the growth stage of childhood-pubertal normal growth In addition, it has the effect of treating and preventing diseases related to growth disorders such as microcertification, dwarfism and poor growth and deterioration of children.

Claims (3)

가시오가피 10∼90중량%, 홍화씨 0.1∼50중량%, 산약 0.1∼50중량%, 산수유 0.1∼50중량%, 복령 0.1∼50중량%, 녹각 0.1∼50중량% 및 인삼 0.1∼50중량%를 포함하는 혼합물로부터 추출된 한약 추출물 100중량부; It contains 10 to 90% by weight, 0.1 to 50% by weight of safflower seeds, 0.1 to 50% by weight, 0.1 to 50% by weight of cornus oil, 0.1 to 50% by weight of Fuling, 0.1 to 50% by weight of green rust, and 0.1 to 50% by weight of ginseng. 100 parts by weight of the herbal extract extracted from the mixture to be; 전분질 분해능이 우수하고, 단백질 분해능이 우수할 뿐 아니라 지방질이나 고분자의 탄수화물을 분해하여 저분자의 아미노산, 핵산, 지방산, 비타민, 알카로이드, 점성이 있는 폴리머(Polymer)를 생산하는 특징이 있는 바실러스 서브틸리스 모리(Bacillus subtilis MORI KCCM 10450)균을 옥수수전분 2중량%, 대두분 1.0중량%, 효모추출물 0.5중량%, 제1인산칼륨 0.1중량%, 소포제 0.02중량%가 함유되고 pH 7.5인 배지에 접종하여 250rpm, 37∼38℃, 통기량 0.3vvm 조건에서 3일간 배양한 다음 탄산칼슘을 배양된 배지 중량의 10%로 넣은 후 교반하면서 투입(inlet)온도 120℃, 출구(outlet)온도 85℃의 조건으로 분사 건조하여 얻은 바실러스 서브틸리스 모리 균의 배양물 0.1∼10중량부; Bacillus subtilis is characterized by excellent starch resolution, excellent protein resolution, and breaks down carbohydrates of fats and polymers to produce low molecular weight amino acids, nucleic acids, fatty acids, vitamins, alkaloids, and viscous polymers. Bacillus subtilis MORI KCCM 10450 was inoculated in a medium containing 2% by weight of corn starch, 1.0% by weight of soybean meal, 0.5% by weight of yeast extract, 0.1% by weight of potassium monophosphate, 0.02% by weight of antifoaming agent and pH 7.5 After culturing for 3 days at 250rpm, 37 ~ 38 ℃, aeration rate 0.3vvm, calcium carbonate was added at 10% of the culture medium weight, and then stirred at inlet temperature of 120 ℃ and outlet temperature of 85 ℃. 0.1 to 10 parts by weight of the culture of Bacillus subtilis S. aureus obtained by spray drying with; 락토바실러스 헬베티쿠스(Lactobacillus helveticus)균을 펩톤 1중량%, 고기추출물 1중량%, 효모 추출물 0.5중량%, 포도당 2중량%, 소르비탄모노올레이트 0.01중량%, 구연산암모늄 0.5중량%, 초산나트륨 0.01중량%, 황산마그네슘 0.01중량%, 황산망간 0.005중량%, 제2인산칼륨 0.2중량%가 포함되고 pH 6.5인 배지에 접종하여 37℃에서 3일간 120rpm으로 진탕 배양한 다음 8,000rpm에서 원심분리하여 락토바실러스 헬베티쿠스만 얻은 뒤 원물 중량의 30%에 해당하는 스킴밀크(skim milk)를 넣은 후 동결 건조하여 얻은 락토바실러스 헬베티쿠스 균의 배양물 5중량부; Lactobacillus helveticus ( Lactobacillus helveticus ) bacteria 1% by weight, meat extract 1%, yeast extract 0.5%, glucose 2% by weight, sorbitan monooleate 0.01% by weight, ammonium citrate 0.5%, sodium acetate Inoculated in a medium containing 0.01% by weight, 0.01% by weight of magnesium sulfate, 0.005% by weight of manganese sulfate, 0.2% by weight of potassium diphosphate, and incubated at 120 rpm for 3 days at 37 ° C, followed by centrifugation at 8,000 rpm. 5 parts by weight of a culture of Lactobacillus helvetticus obtained by only adding Lactobacillus helvetticus and then adding a skim milk (skim milk) corresponding to 30% of the original weight; 및 계면활성제 5중량부를 함유하는 것을 특징으로 하는 성장촉진용 조성물.And 5 parts by weight of a surfactant. 삭제delete 삭제delete
KR1020070056104A 2007-03-07 2007-06-08 Composition Containing Culture of Bacillus subtilis MORI for Growth Promotion Active KR100902947B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070022629 2007-03-07
KR20070022629 2007-03-07

Publications (2)

Publication Number Publication Date
KR20080082417A KR20080082417A (en) 2008-09-11
KR100902947B1 true KR100902947B1 (en) 2009-06-15

Family

ID=40021792

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020070056104A Active KR100902947B1 (en) 2007-03-07 2007-06-08 Composition Containing Culture of Bacillus subtilis MORI for Growth Promotion

Country Status (1)

Country Link
KR (1) KR100902947B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101668067B1 (en) * 2016-05-10 2016-10-24 주식회사 그랜드 코단 Manufacturing method of self cleaning and self growth lawn block based on microbes adsorption

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100936457B1 (en) * 2009-05-13 2010-01-13 주식회사 경희매니지먼트컴퍼니 A making method of fermentational composition
CN109123005A (en) * 2018-09-21 2019-01-04 黑龙江省中医药科学院 A kind of wilsonii fermented tea and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11285378A (en) * 1997-12-01 1999-10-19 Eisai Co Ltd Novel bacillus subtilis having antimicrobial function
KR100404455B1 (en) * 2001-10-09 2003-11-03 학교법인 경희대학교 Growth-promoting effects and pharmaceutical preparations containing the same
KR20040083466A (en) * 2001-12-11 2004-10-02 소시에떼 데 프로듀이 네슬레 소시에떼아노님 Composition for promotion of bone growth and maintenance of bone health

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11285378A (en) * 1997-12-01 1999-10-19 Eisai Co Ltd Novel bacillus subtilis having antimicrobial function
KR100404455B1 (en) * 2001-10-09 2003-11-03 학교법인 경희대학교 Growth-promoting effects and pharmaceutical preparations containing the same
KR20040083466A (en) * 2001-12-11 2004-10-02 소시에떼 데 프로듀이 네슬레 소시에떼아노님 Composition for promotion of bone growth and maintenance of bone health

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101668067B1 (en) * 2016-05-10 2016-10-24 주식회사 그랜드 코단 Manufacturing method of self cleaning and self growth lawn block based on microbes adsorption

Also Published As

Publication number Publication date
KR20080082417A (en) 2008-09-11

Similar Documents

Publication Publication Date Title
KR101661145B1 (en) Composition for preventing or improving non-alcoholic fatty liver disease comprising Dolichos lablab Linne extract as effective component
CA2871478C (en) Pleuropterus multiflorus extract and dipsacus asperoides extract for stimulating the secretion of insulin-like growth factor and promoting bone structure growth, and method for preparing same
KR102020586B1 (en) Healthy foods for elderly comprising animal and plant extracts and process for preparation thereof
CN102994305B (en) Method for preparing health-care food (therapy) product (nutrient juice wine) by use of extracts from cordyceps militaris and cocoon
CN106173548A (en) One carp feed in autumn
KR100902947B1 (en) Composition Containing Culture of Bacillus subtilis MORI for Growth Promotion
KR20190003304A (en) Composition for preventing, improving or treating fatty liver disease comprising Gryllus bimaculatus extract as effective component
KR101252630B1 (en) Useful composition for growth and development of children and youths
KR101626941B1 (en) Composition for Promoting Osteogenesis and Composition for Preventing or Treating Hyperlipidemia
KR20160141027A (en) Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder
KR101040716B1 (en) Feed Additives and Feed Compositions Using Wassons and Methods of Manufacturing Functional Eggs and Functional Eggs Produced by Feeding Same
CN108618128A (en) Adjust the composition and its preparation method and application of immunity
CN111919976A (en) Feed additive for rabbits and application and preparation method thereof
CN114306544B (en) Hypoglycemic composition and preparation method thereof
KR101067335B1 (en) Calcium supplement composition containing Bacillus subtilis SE-4 and fermentation metabolites thereof
WO2008124994A1 (en) A green environmental protection feed additive for fowls and domestic animals and its preparation method
KR101456127B1 (en) A composition for increasing bone growth
KR102470155B1 (en) Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale
KR101322282B1 (en) Composition for bone growth promotion comprising Gelatin hydrolysates
KR101908850B1 (en) Medicinal-Herb Composition Comprising Chinese matrimony vine for Anti-Obesity and the Method of Making the Same
KR102691530B1 (en) Method for increasing anti-obesity compounds of fruits of Cudrania tricuspidata and a composition for improving and preventing obesity comprising the increased anti-obesity compounds
KR101077546B1 (en) A composition having antidiabetes activity consisting of Ligustrum fruit and red-ginseng Cheongkukjang powder
KR20180100030A (en) Composition for treating or preventing postmenopausal syndrome containing herb extract
KR20170143149A (en) Composition for promoting growth comprising medicinal herb extracts
JP2017206477A (en) Myogenesis promoting composition

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U11-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20130609

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

K11-X000 Ip right revival requested

St.27 status event code: A-6-4-K10-K11-oth-X000

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130609

St.27 status event code: N-4-6-H10-H13-oth-PC1903

PR0401 Registration of restoration

St.27 status event code: A-6-4-K10-K13-oth-PR0401

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R401 Registration of restoration
FPAY Annual fee payment

Payment date: 20140609

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20150616

Year of fee payment: 7

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20160607

Year of fee payment: 8

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20170607

Year of fee payment: 9

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 10

St.27 status event code: A-4-4-U10-U11-oth-PR1001

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20190611

Year of fee payment: 11

PR1001 Payment of annual fee

Fee payment year number: 11

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 12

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 13

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 14

St.27 status event code: A-4-4-U10-U11-oth-PR1001

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

PR1001 Payment of annual fee

Fee payment year number: 15

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 16

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 17

St.27 status event code: A-4-4-U10-U11-oth-PR1001